CBD Global Sciences Inc. (CBDNF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist CBD Global Sciences Inc. (CBDNF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 38/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026CBD Global Sciences Inc. (CBDNF) Gesundheitswesen & Pipeline-Uebersicht
CBD Global Sciences Inc. operates in the CBD market, engaging in farming, processing, and manufacturing CBD products. With brands like Aethics and CannaOil, the company caters to the growing demand for CBD-based solutions, facing competition and regulatory challenges in the evolving healthcare landscape.
Investmentthese
Investing in CBD Global Sciences Inc. presents a high-risk, high-reward scenario. The company's negative P/E ratio of -0.20 and a significantly negative profit margin of -3469.4% indicate substantial financial challenges. A gross margin of 24.6% suggests some ability to generate profit from sales, but operational inefficiencies weigh heavily. The company's beta of 0.43 suggests lower volatility compared to the market. Growth depends on successful brand building, market penetration, and navigating regulatory hurdles. Key catalysts include potential changes in legislation that could broaden market access and increased consumer acceptance of CBD products. The company's ability to scale operations efficiently and achieve profitability will be critical for long-term success.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.00B indicates the company's small size and potential for growth, but also higher risk.
- Negative P/E ratio of -0.20 reflects the company's current lack of profitability.
- Profit Margin of -3469.4% highlights significant operational challenges and high expenses relative to revenue.
- Gross Margin of 24.6% suggests potential for profitability if operational efficiencies are improved.
- Beta of 0.43 indicates lower volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Established brands: Aethics, CannaOil, and Strasburg Pharms.
- Vertically integrated operations.
- Proprietary formulations for CBD products.
Schwaechen
- Negative profitability and high operating expenses.
- Small market capitalization.
- Limited financial resources.
Katalysatoren
- Upcoming: Potential changes in legislation that could broaden market access for CBD products.
- Ongoing: Increasing consumer acceptance of CBD products for wellness and therapeutic applications.
- Ongoing: Expansion of distribution networks and partnerships with retailers.
- Upcoming: Potential for new product launches and innovative formulations.
- Ongoing: Research and development efforts to explore new therapeutic applications of CBD.
Risiken
- Ongoing: Regulatory uncertainty and evolving legal landscape.
- Ongoing: Intense competition from established and emerging players.
- Potential: Fluctuations in raw material prices.
- Potential: Changing consumer preferences and market trends.
- Ongoing: Negative profitability and high operating expenses.
Wachstumschancen
- Expansion into new therapeutic areas represents a significant growth opportunity for CBD Global Sciences Inc. The company can invest in research and development to explore the potential of CBD in addressing specific health conditions, such as anxiety, pain management, and sleep disorders. Positive clinical trial results and subsequent regulatory approvals could lead to the development of novel CBD-based therapies, opening up new revenue streams and market segments. This expansion requires strategic partnerships with research institutions and healthcare providers.
- Geographic market expansion offers another avenue for growth. CBD Global Sciences Inc. can target new regions with favorable regulatory environments and growing consumer demand for CBD products. This expansion could involve establishing distribution networks, partnering with local retailers, or setting up operations in new countries. Careful market research and adaptation of product offerings to local preferences are essential for success. The global CBD market is projected to reach billions of dollars in the coming years, providing ample opportunities for growth.
- Development of innovative CBD product formulations can drive revenue growth. CBD Global Sciences Inc. can invest in research and development to create new and improved CBD products, such as enhanced edibles, topical creams, and transdermal patches. These innovative products can cater to specific consumer needs and preferences, differentiating the company from competitors. Collaborations with formulation experts and technology providers can accelerate the development process and ensure product quality and efficacy.
- Strategic partnerships with established healthcare companies can provide access to new markets and distribution channels. CBD Global Sciences Inc. can collaborate with pharmaceutical companies, nutraceutical manufacturers, or healthcare providers to co-develop and market CBD products. These partnerships can leverage the expertise and resources of established players, accelerating market penetration and building brand credibility. Due diligence and careful negotiation are essential to ensure mutually beneficial partnerships.
- Focus on sustainable and ethical sourcing of CBD can enhance brand reputation and attract environmentally conscious consumers. CBD Global Sciences Inc. can implement sustainable farming practices, obtain certifications for organic and fair-trade CBD, and promote its commitment to environmental stewardship. This focus on sustainability can differentiate the company from competitors and appeal to a growing segment of consumers who prioritize ethical and environmentally responsible products. Transparency and traceability throughout the supply chain are crucial for building trust with consumers.
Chancen
- Expansion into new therapeutic areas.
- Geographic market expansion.
- Development of innovative CBD product formulations.
- Strategic partnerships with established healthcare companies.
Risiken
- Regulatory uncertainty and evolving legal landscape.
- Intense competition from established and emerging players.
- Fluctuations in raw material prices.
- Changing consumer preferences and market trends.
Wettbewerbsvorteile
- Brand recognition through Aethics, CannaOil, and Strasburg Pharms brands.
- Vertically integrated operations, controlling aspects of the supply chain from cultivation to product distribution.
- Proprietary formulations and manufacturing processes for CBD products.
Ueber CBDNF
CBD Global Sciences Inc., established in 2018 and headquartered in Lakewood, Colorado, operates within the cannabidiol (CBD) sector. The company's core business revolves around CBD farming, processing, and the manufacturing of a diverse range of CBD products. These products are marketed under several brand names, including Aethics, CannaOil, and Strasburg Pharms. The company cultivates biomass, extracts CBD oil, and formulates various CBD-infused products aimed at capitalizing on the increasing consumer interest in CBD for wellness and therapeutic applications. CBD Global Sciences seeks to establish a vertically integrated operation, controlling aspects of the supply chain from cultivation to product distribution. The company aims to differentiate itself through product quality, branding, and strategic partnerships within the evolving CBD market.
Was das Unternehmen tut
- Farming of cannabidiol (CBD) biomass.
- Processing of CBD biomass to extract CBD oil.
- Manufacturing of CBD oil products.
- Marketing and sales of CBD products under the Aethics brand.
- Marketing and sales of CBD products under the CannaOil brand.
- Marketing and sales of CBD products under the Strasburg Pharms brand.
Geschaeftsmodell
- Cultivation of hemp to produce CBD-rich biomass.
- Extraction and refinement of CBD oil from the biomass.
- Formulation and manufacturing of various CBD products, including oils, tinctures, edibles, and topicals.
- Distribution and sale of CBD products through online channels, retail partnerships, and wholesale agreements.
Branchenkontext
CBD Global Sciences Inc. operates within the rapidly evolving CBD industry, a segment of the broader healthcare market. The industry is characterized by increasing consumer demand for CBD products, driven by perceived wellness benefits. However, the market is also highly competitive, with numerous players vying for market share. Regulatory uncertainty remains a significant challenge, as laws governing CBD production, distribution, and marketing vary widely across jurisdictions. The company faces competition from established players in the pharmaceutical, nutraceutical, and consumer goods industries, as well as smaller, specialized CBD companies. Success in this market requires effective branding, product innovation, and navigating the complex regulatory landscape.
Wichtige Kunden
- Consumers seeking CBD products for wellness and therapeutic purposes.
- Retailers and distributors of CBD products.
- Wholesale customers, including healthcare providers and other businesses.
Finanzdaten
Chart & Info
CBD Global Sciences Inc. (CBDNF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CBDNF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CBDNF.
Kursziele
Wall-Street-Kurszielanalyse fuer CBDNF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CBDNF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Brad Wyatt
CEO
Brad Wyatt serves as the CEO of CBD Global Sciences Inc. His background includes experience in the cannabis and hemp industries, with a focus on business development and strategic partnerships. He has been involved in various aspects of the industry, from cultivation to product manufacturing and distribution. Wyatt's expertise lies in identifying market opportunities, building relationships with key stakeholders, and driving revenue growth. He has a track record of successfully launching new products and expanding market share in the competitive CBD market.
Erfolgsbilanz: Under Brad Wyatt's leadership, CBD Global Sciences Inc. has focused on expanding its product portfolio and distribution network. Key achievements include the development of new CBD product formulations and the establishment of partnerships with retailers and distributors. The company has also worked to enhance its brand recognition and build a loyal customer base. Wyatt has overseen the company's efforts to navigate the complex regulatory landscape and ensure compliance with all applicable laws and regulations.
CBDNF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that CBDNF may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, defunct businesses, or companies with questionable operations.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in CBDNF.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or manipulation is higher on the OTC market.
- OTC Other tier stocks are subject to less regulatory oversight.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's liquidity and trading volume.
- Consult with a qualified financial advisor.
- The company has been in operation since 2018.
- The company has established brands: Aethics, CannaOil, and Strasburg Pharms.
- The company has a CEO in place.
CBD Global Sciences Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CBDNF?
CBD Global Sciences Inc. (CBDNF) currently holds an AI score of 38/100, indicating low score. Key strength: Established brands: Aethics, CannaOil, and Strasburg Pharms.. Primary risk to monitor: Ongoing: Regulatory uncertainty and evolving legal landscape.. This is not financial advice.
How frequently does CBDNF data refresh on this page?
CBDNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBDNF's recent stock price performance?
Recent price movement in CBD Global Sciences Inc. (CBDNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brands: Aethics, CannaOil, and Strasburg Pharms.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBDNF overvalued or undervalued right now?
Determining whether CBD Global Sciences Inc. (CBDNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBDNF?
Before investing in CBD Global Sciences Inc. (CBDNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CBDNF to a portfolio?
Potential reasons to consider CBD Global Sciences Inc. (CBDNF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established brands: Aethics, CannaOil, and Strasburg Pharms.. Additionally: Vertically integrated operations.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CBDNF?
Yes, most major brokerages offer fractional shares of CBD Global Sciences Inc. (CBDNF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CBDNF's earnings and financial reports?
CBD Global Sciences Inc. (CBDNF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CBDNF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available for OTC-listed companies.
- Financial data may be outdated or incomplete.